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Background: We evaluated the clinical relevance of pretransplant donor-specific HLA anti-
bodies (DSA) in renal transplantation patients who had negative T-cell cytotoxicity cross-
matches. 
Methods: From 328 consecutive renal transplant recipients, we selected 28 patients who 
had positive pretransplant (historical or at the time of transplantation) flow cytometry cross-
matches, but negative T-cell cytotoxicity crossmatches at the time of transplantation. The 
presence of DSA and its level at the time of transplantation were retrospectively tested us-
ing Luminex single antigen assays. 
Results: DSA was present in 16 (57.1%) of 28 patients. Biopsy-proven acute rejection (9 
patients) occurred more frequently in patients with DSA than in those without DSA (56.3% 
vs. 0.0%; P=0.003). The positivity rate of class II DSA was significantly higher in patients 
with antibody-mediated rejection (AMR) than in those without AMR (100% vs. 21.7%; P= 
0.003). However, the positivity rate of class I DSA was not different between the two groups 
(40% vs. 40.9%). Among patients with class II DSA, those with AMR tended to have high-
er antibody levels (median fluorescence intensity, MFI) than those without AMR (16,359 
vs. 5,910; P=0.056). A cut-off MFI value of 4,487 for class II DSA predicted the occurrence 
of AMR with good sensitivity and specificity (100% and 87.0%). 
Conclusions: In patients with negative T-cell cytotoxicity crossmatches, the presence of 
class II DSA and its level at the time of transplantation were associated with the occurrence 
of AMR. Pretransplant DSA measurement with Luminex single antigen assay would be 
useful in renal transplantation.
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INTRODUCTION
Identifying acceptable donors for recipients with anti-HLA anti-
bodies is one of the most difficult problems in kidney transplan-
tation. Recently, solid-phase assays, such as the Luminex assay, 
have become available. These assays detect and quantify do-
nor-specific HLA antibodies (DSA) to a degree that was not pos-
sible using cell-based crossmatch tests [1, 2]. When single HLA 
antigen-coated beads are used, these assays provide a relative 
indication of DSA level through the median fluorescence inten-
sity (MFI) of the beads. Although the presence of pretransplant 
DSA has generally been considered to be a risk factor for anti-
body-mediated rejection (AMR) and graft loss [3-6], the clinical 
relevance of low levels of DSA is still debated [7, 8]. The clinical 
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significance of DSA detected solely by using more sensitive as-
says, such as solid phase assays, or flow cytometry crossmatch 
(FCXM), are not certain. Some researchers have reported that 
high levels of DSA at baseline (prior to initiation of desensitiza-
tion), in historical peak sera, or after desensitization therapy are 
associated with increased risk of AMR [9-11]. However, other 
researchers found no association between the level of DSA and 
occurrence of AMR [4, 7, 8]. 
  Renal transplantation is usually performed in patients with a 
negative T-cell complement-dependent cytotoxicity (CDC) cross-
match at the time of transplantation. The aim of this study was 
to investigate whether the risk of acute graft injury and graft loss 
is related to the level of DSA in these patients at the time of trans-
plantation.
METHODS
1. Study design
We selected 28 patients with positive FCXM (T and/or B) results 
at the time of transplantation or in their historical sera from 328 
consecutive ABO-compatible renal transplants performed be-
tween June 2005 and May 2009 at the Seoul National University 
Hospital. The demographics and clinical characteristics of the 
study patients are shown in Table 1. Twelve of the 28 patients 
underwent pretransplant desensitization therapy, and all 28 pa-
tients had negative T-cell CDC crossmatch at the time of trans-
plantation. Serum samples taken at the time of transplantation 
were retrospectively screened for the presence of class I and 
class II HLA antibodies with Luminex screening assay kits. Se-
rum from the 12 patients who received desensitization therapy 
was also tested with Luminex screening assays using samples 
taken just before the initiation of desensitization therapy and 
samples taken at the time of transplantation. 
  Sera that were obtained at the time of transplantation and 
tested positive in the Luminex screening assay (19 HLA class I 
and 13 HLA class II) were tested with Luminex single antigen 
assay kits to determine the level of class I and class II DSA. We 
evaluated the relationship between the presence of DSA and its 
level and the occurrence of biopsy-proven acute rejection (AR) 
and graft survival. All clinical data available through June 2010 
were included in this analysis, and patients were followed for a 
median of 33.3±14.6 months (1-58 months).
2. HLA crossmatch test
T-cell CDC crossmatch was performed according to the National 
Institutes of Health Basic and additional Antiglobulin-enhanced 
Table 1. Demographics and clinical characteristics of the study pa-
tients
All
(N=28)
DSA (+) 
(N=16)
DSA (–)
(N=12)
P
Recipient
  Gender, males, n (%) 8 (29) 3 (19) 5 (42) NS
  Age, median (range) 47 (14-67) 47 (29-67) 44 (14-57) NS
Donor
  Deceased donor, n (%) 3 (11) 3 (19) 0 (0) NS
  Gender, males, n (%) 16 (57) 9 (56) 7 (58) NS
  Age, median (range) 36 (18-62) 34 (18-62) 37 (20-55) NS
Sensitizing events*, n (%) 20 (71) 12 (75) 8 (67) NS
Desensitization therapy, n (%) 12 (43) 7 (44) 5 (42) NS
Induction therapy, n (%)
  None 8 (29) 4 (25) 4 (33) NS
  Basiliximab 20 (71) 12 (75) 8 (67) NS
Immunosuppression, n (%)
  Tac-MMF-Pd 20 (71) 11 (69) 9 (75) NS
  CsA-MMF-Pd 8 (29) 5 (31) 3 (25) NS
HLA-A/B mismatches, n (%)
  0 0 (0) 0 (0) 0 (0) NS
  1 4 (14) 3 (19) 1 (8) NS
  2 18 (64) 10 (63) 8 (67) NS
  3 3 (11) 3 (19) 0 (0) NS
  4 3 (11) 0 (0) 3 (25) NS
HLA-DR mismatches, n (%)
  0 5 (18)  2 (13) 3 (25) NS
  1 17 (61) 9 (56) 8 (67) NS
  2 6 (21) 5 (31) 1 (8) NS
T-CDC crossmatches (+), n (%)
  Historical 2/25 (8) 2/13 (15) 0/12 (0) NS
  Current 0/28 (0) 0/16 (0) 0/12 (0) NS
Flow crossmatches (+), n (%)
  Historical: T and/or B  20/25 (80) 10/13 (77) 10/12 (83) NS
    T  18/25 (72) 8/13 (62) 10/12 (83) NS
    B  8/22 (36) 4/11 (36) 4/11 (36) NS
  Current: T and/or B  14/28 (50) 8/16 (50) 6/12 (50) NS
    T  7/28 (25) 3/16 (19) 4/12 (33) NS
    B
†  8/28 (29) 6/16 (38) 2/12 (17) NS
*Prior transplants, blood transfusion, or pregnancies; 
†including 2 cases in 
DSA (+) group and 2 cases in DSA (–) group, which were not interpretable 
due to the interference of rituximab.
Abbreviations: DSA, donor-specific HLA antibodies; NS, not significant (P> 
0.05); CDC, complement-dependent cytotoxicity.Song EY, et al.
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Methods. FCXM was performed using a pronase-treated T/B 
single tube assay, as previously described [12]. T and B lympho-
cytes were stained with peridinin chlorophyll protein (PerCP)-
conjugated and phycoerythrin (PE)-conjugated mouse mono-
clonal antibodies specific for human CD3 and CD19, respec-
tively (BD Bioscience, San Jose, CA, USA). The presence of 
bound antibodies was determined using fluorescein isothiocya-
nate (FITC)-conjugated anti-human IgG (Jackson Immunore-
search Laboratories Inc., West Grove, PA, USA). Fluorescence 
was analyzed using a FACSCalibur flow cytometer (BD Biosci-
ence). FCXM results are expressed as the ratio of test serum 
MFI to normal human AB type serum MFI. T-cell and B-cell 
FCXMs were considered to be positive when the MFI ratio was 
≥2.0. At the time of transplantation, all patients had negative T-
cell CDC crossmatches, and FCXM assays indicated, 6 patients 
were positive for T-cell only, 7 patients for B-cell only, and 1 pa-
tient for both T- and B-cell antibodies. The B-cell FCXM results 
of 2 patients who were positive for DSA and 2 patients negative 
for DSA were not interpretable due to rituximab interference 
(Table 1).
3. Detection of DSA
HLA antibody screening was performed with LIFECODES Life-
Screen Deluxe kit (Gen-probe, Stamford, CT, USA). We per-
formed HLA antibody identification in 28 HLA antibody-positive 
sera that were obtained at the time of transplantation (19 HLA 
class I and 13 HLA class II), using LIFECODES LSA class I and 
class II kits (Gen-probe) according to the manufacturer’s in-
structions. Briefly, 10 µL of serum sample were added to micro-
plate well, then 40 µL of HLA class I or class II single antigen 
Luminex beads were added, and incubated in the dark for 30 
min at room temperature. After washing with wash buffer, 50 µL 
of goat anti-human IgG secondary antibody conjugated with 
phycoerythrin was added to the beads and samples were again 
incubated for 30 min in the dark at room temperature. After 
washing, the samples were read using the Luminex 200
TM sys-
tem (Luminex Corp. Austin, TX, USA). The cut-off MFI of posi-
tive reaction for each DSA bead was defined as 500. DSA levels 
were determined by the sum of MFI values for each DSA class: 
class I (HLA-A, HLA-B), class II (HLA-DR, HLA-DQ), and total 
(class I+II). HLA-DQ typing of donors was performed to deter-
mine donor-specificity when DQ antibodies were detected. 
4. Desensitization protocol
The 12 patients who received desensitization treatment began 
taking mycophenolate mofetil (MMF, 750 mg twice daily, p.o.) 
and tacrolimus (0.05 mg/kg twice daily, p.o., target trough level 
10-12 ng/mL) two days before their first plasmapheresis treat-
ment (one plasma volume exchange with 4% albumin and/or 
fresh frozen plasma). Plasmapheresis was performed 3 to 7 times 
preoperatively, every other day. Intravenous immunoglobulin 
(100 mg/kg) was administered immediately after each plasma-
pheresis treatment. Methylprednisolone 1,000 mg i.v. was started 
at the time of the surgery, and the steroid dose was tapered to 
an oral dose of prednisolone. Combined immunosuppression 
with MMF, tacrolimus and prednisolone was continued through 
the post-transplantation period. The first 2 desensitization pa-
tients received 10 days of OKT3 (muromonab-CD3; 5 mg daily, 
i.v.) after transplantation. The remaining 10 patients received 
rituximab (375 mg/m
2 of body surface area, i.v.) instead of OKT3. 
Rituximab was administered 3 days before the first plasmapher-
esis treatment and again 1 day before transplantation.
5. Detection and treatment of rejection
Biopsies were performed for all recipients with suspected rejec-
tion episodes. The biopsies were graded using the Banff 97 clas-
sification [13]. AMR was defined by C4d deposition [14]. Acute 
cellular rejection (ACR) was treated with methylprednisolone 
pulse therapy (1,000 mg/day for 3 days). AMR was treated with 
plasmapheresis followed by intravenous immunoglobulin (100 
mg/kg), rituximab (375 mg/m
2 of body surface area, i.v.), and 
methylprednisolone pulse therapy. 
6. Statistical analysis
Quantitative variables were expressed as the mean (standard 
deviation) for normally distributed data or the median (interquar-
tile range, IQR) for non-normally distributed data. Categorical 
variables were expressed as absolute and relative frequencies. 
Continuous variables were compared using Mann-Whitney U 
tests and categorical variables using chi-square tests or Fisher’s 
exact tests, as appropriate. ROC curve analysis was computed 
for each predictor. All tests were 2-sided and used a significance 
level of 0.05. Data handling and analysis were performed with 
SPSS software for Windows, version 12.0 (SPSS Inc., Chicago, 
IL, USA).
RESULTS
The HLA antibody levels of patients undergoing desensitization 
therapy were tested before therapy and at the time of transplan-
tation using the MFI values of pooled antigen beads from Lu-
minex screen tests. Patients had significantly lower levels of HLA Song EY, et al.
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class I after therapy than before the start of desensitization ther-
apy (median [IQR], 1,971 [1,355-3,599] vs. 645 [461-2,754]; P< 
0.01). There was a similar, though non-significant, tendency for 
HLA class II levels to be lower at the time of transplantation than 
they were before desensitization therapy began (median [IQR], 
3,604 [1,652-5,788] vs. 1,711 [1,141-3,471]).
  Of the 28 patients tested, 16 (57.1%) had DSA at the time of 
transplantation. The relationship between pretransplant DSA 
and occurrence of acute rejection and graft survival was ana-
lyzed in 27 patients (Table 2). One patient negative for DSA was 
excluded from the analysis, because the graft loss that occurred 
within 24 hr of transplantation was due to a clinically suspected 
vascular problem rather than to antibody mediated hyperacute 
rejection. Pathologic findings of extensive ischemic necrosis, 
subcapsular hemorrhage and congestion were observed in this 
patient. Nine patients had biopsy-proven acute rejection: 4 ACR, 
3 AMR, 2 ACR+AMR. There was a significantly higher rate of 
biopsy-proven acute rejection among patients with DSA at the 
time of transplantation than among those without DSA (56.3% 
vs. 0.0%; P=0.003). The incidence of AMR (±ACR) tended to 
be higher in patients with DSA than in those without DSA (31.3% 
vs. 0.0%; P=0.060). However, 3 yr graft survival was not signifi-
cantly different between the two groups of patients (83.3% vs. 
100.0%). 
  The relationship between pretransplant DSA and occurrence 
of AMR is shown in Table 3. Among the 27 patients evaluated, 6 
patients had only class I DSA, 5 patients had only class II DSA, 
and 5 patients had both class I and class II DSA. The proportion 
of patients positive for class II DSA at the time of transplantation 
was significantly higher in patients with AMR than in those with-
out AMR (100% vs. 22.7%; P=0.003). However, the proportion 
of patients positive for class I DSA was not different between the 
two groups (40% vs. 40.9%). The number of DSA was signifi-
cantly higher in patients with AMR than in those without AMR 
(median [IQR], 3 [2.5-3.5] vs. 0 [0-1]; P=0.001). 
  In patients with class II DSA, the antibody level (MFI sum 
value) tended to be higher in patients with AMR than in those 
without AMR (median [IQR], 16,359 [12,061-20,538] vs. 5,910 
[3,687-6,555]; P=0.056; Table 3, Fig. 1). However, class I DSA 
level was not significantly different between the two groups. 
  Pretransplant (at the time of transplantation) class II DSA lev-
els that were associated with the occurrence of AMR were eval-
uated by ROC curve analysis. The occurrence of AMR was pre-
dicted with good sensitivity and specificity (100% and 87.0%) 
using a cut-off MFI value of 4,487 for class II DSA. The area un-
der the curve (AUC) was 0.974 (95% CI, 0.915-1.033). 
DISCUSSION
In this study, pretransplant DSA was significantly associated with 
the occurrence of acute rejection in T-cell cytotoxicity cross-
match-negative patients (Table 2). Specifically, the presence of 
HLA class II DSA at the time of transplantation was significantly 
associated with the occurrence of AMR (Table 3). This finding is 
Table 2. Relationship between DSA at the time of transplantation 
and biopsy-proven acute rejection
DSA (+)
(N=16)
DSA (–)
(N=11)* P
AR 9 (56.3%) 0 (0.0%) 0.003
AMR±ACR 5 (31.3%) 0 (0.0%) 0.060
ACR only 4 (25.0%) 0 (0.0%) 0.123
1-yr GS 14/15 (93.3%) 11/11 (100.0%) 1.000
3-yr GS 5/6 (83.3%) 7/7 (100.0%) 0.462
*One case in the DSA (–) group was excluded, because graft loss within 24 
hr of transplantation was due to clinically suspected vascular problem rather 
than antibody-mediated hyperacute rejection.
Abbreviations: DSA, donor-specific HLA antibodies; AR, acute rejection; ACR, 
acute cellular rejection; AMR, antibody-mediated rejection; GS, graft survival.
Table 3. Relationship between DSA at the time of transplantation 
and antibody-mediated rejection 
AMR
(N = 5)
No AMR
(N = 22)
P
DSA positivity
  Class I  2 (40.0%)  9 (40.9%) 1.000
  Class II  5 (100.0%)  5 (22.7%) 0.003
  Class I only 0 (0.0%)  6 (27.3%) 0.555
  Class II only  3 (60.0%)  2 (9.1%) 0.030
  Class I + II  2 (40.0%)   3 (13.6%) 0.221
  Class I or II   5 (100.0%) 11 (50.0%) 0.060
Number of DSA*  3 (2.5-3.5) 0 (0-1) 0.001
Level of DSA
†
  Class I 2,957 (2,954-2,960) 3,127 (2,067-7,232) 0.909
  Class II 16,359 (12,061-20,538) 5,910 (3,687-6,555) 0.056
Flow crossmatch (+)
  T and/or B 4 (80.0%) 10 (45.5%) 0.326
  T 0 (0.0%) 7 (31.8%) 0.283
  B 4 (80.0%)
‡ 4 (18.2%)
‡ 0.017
*Median (interquartile range); 
†MFI sum value, median (interquartile range); 
‡Including 2 cases that were not interpretable due to the interference of 
rituximab.
Abbreviations: AMR, antibody-mediated rejection; DSA, donor-specific HLA 
antibodies.Song EY, et al.
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in accordance with the results of several recent studies, which 
have shown the importance of class II DSA in the outcome of 
renal transplantation in T-cell crossmatch (flow cytometry or cy-
totoxicity) negative patients [15-17]. The presence of HLA class 
II DSA in patients with negative T-cell FCXM was associated with 
the occurrence of AMR or poor graft survival [15, 16]. Higher 
levels of class II DSA in patients with negative T-cell cytotoxicity 
(AHG) crossmatches were related to increased risk of develop-
ing transplant glomerulopathy and the presence of C4d in peri-
tubular capillaries [17]. 
  In the present study, positive rate of class I DSA or its level was 
not different between patients with AMR and those without AMR 
(Table 3). Although a high level of class I DSA is detrimental to 
allograft survival, low levels of anti-HLA class I antibodies result 
in signaling cascades in endothelial cells that include survival 
proteins and induce accommodation of human allografts [18-20]. 
All studies showing the clinical impact of class II DSA, including 
the present study, were performed using patients with negative 
T-cell crossmatches (flow cytometry or cytotoxicity). Therefore, 
patients with high levels of class I antibodies were probably not 
included in any of these studies. Even if some of the patients in 
these studies had low levels of HLA class I antibodies, the anti-
bodies might have assisted allograft accommodation, rather than 
adversely affect allografts. Such an effect may partially explain 
the lack of association of HLA class I antibodies with poor graft 
outcome in the patients in our study. Further studies of the ef-
fects of low levels of HLA class II antibodies on signaling cas-
cades in endothelial cells are needed to clarify the roles of both 
HLA class I and class II antibodies in renal transplantation. 
  In the present study, the level of pretransplant class II DSA 
was associated with the occurrence of AMR (Table 3, Fig. 1). In 
ROC curve analysis, the cut-off MFI value of 4,487 for class II 
DSA at the time of transplantation predicted the occurrence of 
AMR with good sensitivity and specificity. In patients undergoing 
desensitization therapy, high levels of DSA both before and after 
desensitization therapy, have been reported to be associated 
with increased risk of AMR [9, 11]. Very high levels of baseline 
DSA has been reported to be associated with an increased risk 
of AMR and poor long-term allograft survival [9]. After desensiti-
zation therapy, patients who have DSA with a standard fluores-
cence intensity of  >100,000 and with FCXM median channel 
shift  >200 were found to be at higher risk of AMR than those 
who have lower DSA values [11]. However, the clinical relevance 
of lower levels of DSA is still debated [7, 8]. Recently, the pres-
ence of weak DSA in historical peak sera has been shown to be 
associated with AMR and poor graft survival [10]. MFI cut-off 
values of 465 for the highest single, or 820 for total, DSA showed 
maximal sensitivity and specificity for predicting the occurrence 
of AMR [10]. Further, 8-yr graft survival decreased progressively 
with increasing DSA levels: 82.5% in patients with MFI  <465; 
78.4% with MFI 466-3,000; 60.6% with MFI >3,000 (P<0.001). 
  DSA levels are not directly comparable between different stud-
ies and the differences between the reported levels of DSA with 
clinical significance may result from many factors. These include 
lack of standardization of MFI values in Luminex assays, differ-
ences in the method of DSA calculation, the extent (DQ, DP) 
and resolution of HLA typing in donors and recipients, and the 
density of HLA molecules on single antigen beads [21]. Further 
efforts are needed to standardize these sources of variability in 
order to determine the level of DSA that has clinical significance. 
  In conclusion, the presence of class II DSA and its level at the 
time of transplantation were associated with the occurrence of 
AMR in renal transplantation patients with negative T-cell cyto-
toxicity crossmatches. Pretransplant DSA measurement using 
single antigen Luminex bead assays would be useful for prevent-
ing AMR and post-operative follow up in renal transplantation.
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Fig. 1. Class II donor-specific HLA antibody (DSA) levels at the time 
of transplantation in patients with or without antibody mediated re-
jection (AMR). Filled and open circles represent DSA positive and 
negative cases, respectively. MFI sum values of DSA are plotted. 
Bars indicate median DSA value of the positive cases in each group.
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